January 28-31, 2027
Westin San Diego Bayview
San Diego, California

sign up to request additional information

COnference Cochairs

Ryan B. Corcoran, Massachusetts General Hospital, Boston, Massachusetts
Julian Downward, Cancer Research UK London Research Institute, London, England
Ignacio Garrido-Laguna, Moffitt Cancer Center, Tampa, Florida
Sandra Misale, Johns Hopkins University School of Medicine, Baltimore, Maryland

For decades, RAS was considered one of cancer biology’s most important and challenging therapeutic targets. Today, the field stands at a pivotal moment. The emergence of direct RAS inhibitors, novel combination strategies, and a deeper understanding of RAS signaling networks has transformed what was once viewed as an “undruggable” pathway into a rapidly evolving therapeutic landscape.

Bringing together leaders from academia, industry, and clinical oncology, the conference will explore how advances in structural biology, chemical biology, omics, and immunology continue to shape our understanding of RAS-driven cancers and guide therapeutic approaches. Special emphasis will be placed on emerging therapeutic vulnerabilities, mechanisms of response and resistance, and opportunities to improve outcomes across multiple tumor types, including pancreatic, colorectal, lung, melanoma, and hematologic malignancies. 

As RAS-targeted agents enter clinical practice and new generations of inhibitors advance through development, fundamental questions remain regarding resistance, pathway adaptation, tumor heterogeneity, and optimal therapeutic combinations. A dedicated session will spotlight promising clinical trial discoveries from submitted abstracts that have the potential to impact future therapeutic strategies.

Please Note: All presentations at this event represent the opinions of the presenter and do not represent the position or the opinion of the AACR or its members.